Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta‐Analysis of More Than 20 000 Patients

Figures

• 

  Figure 1. The Preferred Reporting of Items for Systematic Meta‐Analysis flowchart. VEGF indicates vascular endothelial growth factor

• 

  Figure 2. Overall estimate and estimates from each study of the risk ratio (RR) of arterial adverse events associated with bevacizumab treatment. The first author and the publication year were used for each study. The total number of events and the sample size are shown for each study. The weight of each study in the final analysis is indicated as a percentage. The RR for each study is shown numerically on the left and graphically on the right. Square boxes denote the risk ratio, horizontal lines represent 95% CIs, and the diamond plot represents the overall results of the included trials. Weights are from a fixed‐effects analysis. M‐H indicates Mantel‐Haenszel statistical method.

• 

  Figure 3. Overall estimate and estimates from each study of the risk ratio (RR) of cardiac ischemia associated with bevacizumab treatment (A), cardiac ischemia associated with high‐dose bevacizumab treatment (B), cerebral ischemia associated with bevacizumab treatment (C), and cerebral ischemia associated with a high‐dose bevacizumab regimen (D). The first author and the publication year were used for each study. The total number of events and sample size are shown for each study. The weight of each study in the final analysis is shown in percentages. The RR for each study is shown numerically on the left and graphically on the right. Square boxes denote the RR, horizontal lines represent 95% CIs, and the diamond plot represents overall results of the included trials. Weights are from fixed‐effects analysis. M‐H indicates Mantel‐Haenszel statistical method.

• 

  Figure 4. Overall estimate and estimates from each study of the risk ratio (RR) of venous adverse events associated with bevacizumab treatment. The first author and the publication year were used for each study. The total number of events and the sample size are shown for each study. The weight of each study in the final analysis is indicated as a percentage. The RR for each study is shown numerically on the left and graphically on the right. Square boxes denote the RR, horizontal lines represent 95% CIs, and the diamond plot represents the overall results of the included trials. Weights are from a fixed‐effects analysis.

• 

  Figure 5. Overall estimate and estimates from each study of the risk ratio (RR) of bleeding (A) and risk of bias for bleeding (B) associated with bevacizumab treatment. The first author and the publication year were used for each study. The total number of events and the sample size are shown for each study. The weight of each study in the final analysis is indicated as a percentage. The relative risk for each study is shown numerically on the left and graphically on the right. Square boxes denote the RR, horizontal lines represent 95% CIs, and the diamond plot represents the overall results of the included trials. Weights are from a fixed‐effects analysis. Each dot represents one study included in the analysis of bleeding events. The SE (log RR) axis represents study precision, and the risk ratio (RR) axis shows the study results. M‐H indicates Mantel‐Haenszel statistical test.

• 

  Figure 6. Overall estimate and estimates from each study of the risk ratio (RR) of arterial hypertension (A) and risk of bias for arterial hypertension (B) associated with bevacizumab treatment. The first author and the publication year were used for each study. The total number of events and the sample size are shown for each study. The weight of each study in the final analysis is indicated as a percentage. The relative risk for each study is shown numerically on the left and graphically on the right. The square boxes denote the RR, horizontal lines represent 95% CIs, and the diamond plot represents the overall results of the included trials. Weights are from a fixed‐effects analysis. Each dot represents one study included in the analysis of bleeding events. The SE (log risk ratio [RR]) axis represents study precision, and the RR axis shows the study results. M‐H indicates Mantel‐Haenszel statistical method.